Natco Pharma Updates on Risdiplam Launch Amid Legal Proceedings

As of 11:32 AM on April 8, 2025, Natco Pharma’s share price witnessed an uptick of around 2%, following a legal update released by the company regarding its planned launch of a generic version of Risdiplam in India. The announcement has sparked investor interest due to its potential implications for both market competition and patient access.

Court Proceedings: Status Quo Maintained

Natco Pharma clarified that the Delhi High Court’s Single Judge had earlier denied Roche’s request for an injunction to block Natco’s launch of the generic version of Risdiplam, a treatment typically used for spinal muscular atrophy (SMA). However, Roche has since appealed that ruling, and the Appellate Bench has now directed that a status quo be maintained until the appeal is resolved.

Due to the ongoing nature of the litigation, Natco has chosen not to comment further on the legal proceedings. The company reaffirmed that any product launch will only occur after obtaining a clear verdict from the Appellate Bench, which is expected in the near future.

Planned Pricing and Access

In line with its earlier submissions to the court, Natco has proposed to launch the product at a Maximum Retail Price (MRP) of ₹15,900. Additionally, it plans to support patients through a patient access programme, offering discounts to those deemed eligible.

This strategy reflects Natco’s long-standing focus on affordability and accessibility in critical therapy areas such as oncology and rare diseases.

About Natco Pharma

Headquartered in Hyderabad, Natco Pharma Limited is a research-driven pharmaceutical company engaged in the development, manufacturing, and marketing of both generic and branded drugs, as well as crop protection products. The company has nine manufacturing facilities and two R&D centres across India, with approvals from major regulatory bodies including the US FDA and Health Canada.

Its business model includes a strong presence in targeted therapies for the Indian market and a focus on limited competition molecules in the US. Natco serves over 50 global markets and is recognised for its contributions to the pharmaceutical and healthcare landscape.

Conclusion

Natco Pharma’s update on Risdiplam underscores its commitment to affordable healthcare while awaiting legal clarity. Investors and patients alike await the court’s final decision.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.